Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ImmunityBio, Inc. Director's Dealing 2022

Jan 28, 2022

31529_dirs_2022-01-28_8dbeeeae-60c6-4f54-935e-e062461e495c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2021-12-31

Reporting Person: Simon Barry J. (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-04 Common Stock G 71051 Disposed 3031456 Direct